Fibrosis progression in the NASH mouse model was assessed by measuring the relative gene expression levels of liver fibrosis markers, specifically Col1a1 and Acta2, as well as the inflammation marker Mcp1, using RT-qPCR. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.